Still More To Be Done On European Biosimilars
Medicines For Europe Releases Latest Biosimilar Market Review Report
Off-patent industry association Medicines for Europe has released a Biosimilar Market Review report that examines availability, pricing systems, retail markets, hospital tendering, reimbursement systems, healthcare practitioner-related policies, information and education around biosimilars in 26 European countries, concluding that “while progress has been made, it is clear much more can be done.”
You may also be interested in...
European policy makers must act quickly to harness the benefits of biosimilars as part of the new EU Pharma Strategy, Medicines for Europe insists in the wake of the latest annual report on European biosimilar competition.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.